Primary Objectives:
- The primary objective of the study is to evaluate clinical efficacy i.e. to show that
with respect to clinical cure rate, Ketek® (telithromycin) in the treatment of community
acquired respiratory tract infections: community acquired pneumonia (CAP), acute
bacterial exacerbation of chronic bronchitis (AECB) and acute sinusitis (AS), in
outpatients.
Secondary Objectives:
The secondary objectives are to:
- Further assess the efficacy of Ketek® (telithromycin) by considering the rate at which
additional antibacterials were prescribed to treat the primary infection; the rate of
hospitalisation due to a complication of the primary infection and assessment of
bacteriological data, chest X-ray and sinus X-ray if available.
- Evaluate safety of Ketek® (telithromycin) through Adverse Event (AE) and Serious Adverse
Event (SAE) reporting